Cargando…
Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2
COVID-19 [coronavirus disease 2019] has resulted in over 204,644,849 confirmed cases and over 4,323,139 deaths throughout the world as of 12 August 2021, a total of 4,428,168,759 vaccine doses have been administered. The lack of potentially effective drugs against the virus is making the situation w...
Autores principales: | Choudhary, Vikram, Gupta, Amisha, Sharma, Rajesh, Parmar, Hamendra Singh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440732/ https://www.ncbi.nlm.nih.gov/pubmed/34539131 http://dx.doi.org/10.1007/s42485-021-00074-x |
Ejemplares similares
-
Restructuring the ONYX-015 adenovirus by using spike protein genes from SARS-CoV-2 and MERS-CoV: Possible implications in breast cancer treatment
por: Parmar, Hamendra Singh, et al.
Publicado: (2022) -
Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
por: Li, Qizhang, et al.
Publicado: (2020) -
Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021) -
Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020) -
SARS-CoV-2 spike therapeutic antibodies in the age of variants
por: Baum, Alina, et al.
Publicado: (2021)